What is the Work Group's confidence in the quality of the evidence related to the icosapent ethyl drug?
The Work Group's confidence in the quality of the evidence was moderate. Limitations included a small evidence base (i.e., one clinical trial), unclear allocation concealment, and the potential for confounding related to the choice of placebo.